Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

388 ARTÍCULOS , VIENDO DEL 286 AL 300

Neuroprotective and Neurological/Cognitive Enhancement Effects of Curcumin after Brain Ischemia Injury with Alzheimer's Disease Phenotype

Pluta R, Ułamek-Kozioł M, Czuczwar SJ.

Int J Mol Sci. 2018 Dec 12;19(12):4002. doi: 10.3390/ijms19124002.

Biological clocks, some clock-related diseases, and medicinal plants

Deng TS.

Psych J. 2018 Dec;7(4):197-205. doi: 10.1002/pchj.263.

Atypical PKC: therapeutic target for Alzheimer's?

Farese RV, Sajan MP.

Aging (Albany NY). 2018 Dec 20;11(1):13-14. doi: 10.18632/aging.101730.

Liposome delivery systems for the treatment of Alzheimer's disease

Ross C, Taylor M, Fullwood N, Allsop D.

Int J Nanomedicine. 2018 Dec 12;13:8507-8522. doi: 10.2147/IJN.S183117. eCollection 2018.

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials

Dou KX, Tan MS, Tan CC, Cao XP, Hou XH, Guo QH, Tan L, Mok V, Yu JT.

Alzheimers Res Ther. 2018 Dec 27;10(1):126. doi: 10.1186/s13195-018-0457-9.

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis

Kennedy RE, Cutter GR, Fowler ME, Schneider LS.

JAMA Netw Open. 2018 Nov 2;1(7):e184080. doi: 10.1001/jamanetworkopen.2018.4080.

Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential

de Matos AM, de Macedo MP, Rauter AP.

Med Res Rev. 2018 Jan;38(1):261-324. doi: 10.1002/med.21440. Epub 2017 Apr 19.

Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease

Zhao N, Liu CC, Qiao W, Bu G.

Biol Psychiatry. 2018 Feb 15;83(4):347-357. doi: 10.1016/j.biopsych.2017.03.003. Epub 2017 Mar 14.

Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review

Canhada S, Castro K, Perry IS, Luft VC.

Nutr Neurosci. 2018 Oct;21(8):529-538. doi: 10.1080/1028415X.2017.1321813. Epub 2017 May 3.

Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches

Corrêa-Velloso JC, Gonçalves MC, Naaldijk Y, Oliveira-Giacomelli Á, Pillat MM, Ulrich H.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt A):34-53. doi: 10.1016/j.pnpbp.2017.04.033. Epub 2017 May 3.

[Anti-ageing therapies in Alzheimer's disease]

Alonso Abreu GS, Brito Armas JM, Castro Fuentes R.

Rev Esp Geriatr Gerontol. 2018 Jan-Feb;53(1):45-53. doi: 10.1016/j.regg.2017.02.007. Epub 2017 May 24.

Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission

Korábečný J, Nepovimová E, Cikánková T, Špilovská K, Vašková L, Mezeiová E, Kuča K, Hroudová J.

Neuroscience. 2018 Feb 1;370:191-206. doi: 10.1016/j.neuroscience.2017.06.034. Epub 2017 Jul 1.

Mechanistic comparison of current pharmacological treatments and novel phytochemicals to target amyloid peptides in Alzheimer's and neurodegenerative diseases

Ayyalasomayajula N, Suresh C.

Nutr Neurosci. 2018 Dec;21(10):682-694. doi: 10.1080/1028415X.2017.1345425. Epub 2017 Jul 6.

Targeting Fyn Kinase in Alzheimer's Disease

Nygaard HB.

Biol Psychiatry. 2018 Feb 15;83(4):369-376. doi: 10.1016/j.biopsych.2017.06.004. Epub 2017 Jun 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias